Drug intelligence / Profile preview

qianqing granules

Development stage: Phase 2
Lead developer: Hunan Huana Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Qianqing Granules is a Class 1.1 innovative Traditional Chinese Medicine (TCM) developed by Hunan Warner Pharmaceutical Co., Ltd. for the treatment of the common cold, specifically targeting the wind-heat syndrome. Approved by China's National Medical Products Administration (NMPA) in December 2023, the formulation is designed to clear heat, release the exterior, and detoxify. Clinical trials have demonstrated its efficacy in reducing symptoms such as fever, sore throat, cough, and yellow phlegm associated with viral upper respiratory tract infections. As a multi-herb preparation, it utilizes a synergistic pharmacological approach to provide symptomatic relief and support the immune response during the acute phase of a cold.

Brand names: Qianqing Granules
Other names: 乾清颗粒Qián Qīng Kē Lì

Beyond the preview

Go deeper on qianqing granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qianqing granules.